

18 August 2021

## ASX Announcement

### Island Pharmaceuticals granted key Australian patent for ISLA-101

- Island's lead asset, ISLA-101 granted key patent from IP Australia covering a method of treating or preventing dengue and other mosquito borne viruses
- Patent underpins Island's drug repurposing strategy to rapidly and efficiently develop antiviral therapies with a key focus being mosquito borne viral diseases, such as dengue fever.
- Around 390 million people are infected with dengue fever each year<sup>1</sup>, representing a significant unmet need and opportunity.

Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to announce that a key patent relating to the Company's lead program, ISLA-101, has been granted by IP Australia. ISLA-101 is a drug with a very well-known safety profile, being repurposed for mosquito borne viruses.

The Australian patent grant entitled, "Method of Viral Inhibition" was issued under Australian Patent No **2019213440** and has an expiration date of 16 April 2034. The patent covers a method of treating or preventing dengue virus or other mosquito borne virus infections with ISLA-101. Island has licensed the IP portfolio, generated by Monash University.

This is the third patent granted to Island in the last 12 months, adding to an estate that includes patents granted for the same coverage in the United States, Singapore and Brazil.

CEO of Island Pharmaceuticals, Dr David Foster said, "We are excited about the grant of this additional Australian patent, which adds to Island's growing intellectual property portfolio and supports the broad applicability of ISLA-101 for different mosquito bone viruses. Increasingly, we are seeing reports about mosquito borne viral outbreaks in the news. These continue to represent major unmet medical needs, creating a strong market for treatments like ISLA-101. This patent further protects our lead program, which is critical as we advance towards the commencement of clinical trials at the end of this year."

Dengue fever is often seen as predominantly a disease of developing countries. However, global warming has meant that mosquitoes carrying dengue are travelling further, and in the last few years, rising case numbers have been recorded in Florida and, as recently as 2019, in North Queensland. Hundreds of cases per annum have been seen in recent years in FIFO workers in West Australian mines. Dengue is endemic in much of Asia, the South Pacific, South America, Central America and Africa. Around 390 million humans are infected each year, representing a significant unmet need and opportunity. Dengue fever has a significant mortality rate without access to appropriate medical care

#### Approved for release to the ASX by:

Dr Paul MacLeman  
Executive Chairman  
Island Pharmaceuticals Ltd.  
[info@islandpharmaceuticals.com](mailto:info@islandpharmaceuticals.com)

---

<sup>1</sup> Source: <https://www.who.int/news-room/fact-sheets/detail/vector-borne-diseases>



For further information, please contact:

<b>Investors:</b> Jane Lowe IR Department Mobile: +61 411 117 774 <a href="mailto:jane.lowe@irdepartment.com.au">jane.lowe@irdepartment.com.au</a>	<b>Media:</b> Juliana Roadley IR Department Mobile: +61 414 889 863 <a href="mailto:juliana.roadley@irdepartment.com.au">juliana.roadley@irdepartment.com.au</a>
--	--

### **About Island Pharmaceuticals (ASX: ILA)**

Island is clinical-stage drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The Company is advancing toward a Phase II clinical trial in dengue-infected subjects.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) will permit Island to expedite the FDA approval process for a new drug, or sell the PRV in a secondary market.

*Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.*

Visit [www.islandpharmaceuticals.com](http://www.islandpharmaceuticals.com) for more info.